XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Intangible Assets
 6 Months Ended
Jun. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
Intangible assets as of June 29, 2024 and December 30, 2023 consist of the following (in $000’s):
June 29,
2024		December 30,
2023
Soin intangibles *$19,293 $19,293 
Customer relationships13,925 — 
Trade names2,675 — 
Developed technology1,850 — 
Patents and domains$4 $4 
Intangible assets37,747 19,297 
Less accumulated amortization(2,751)(1,451)
Total intangible assets$34,996 $17,846 
*The Soin intangibles acquired by the Company consist of the following:
1.Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain;
2.Final formula for Naltrexone; and
3.Orphan drug designation as approved by the FDA.
Intangible amortization expense was $660,000 and $363,000 for the 13 weeks ended June 29, 2024 and July 1, 2023 and $1.3 million and $726,000 for the 26 weeks ended June 29, 2024 and July 1, 2023.